Novo Nordisk gets US FDA approval for higher-dose Wegovy, as India's generic Semaglutide war begins
Semaglutide went off patent in India on March 20, immediately drawing in generic manufacturers with prices starting as low as Rs 220 a shot. A day earlier, Novo Nordisk had secured US FDA approval for a higher-dose Wegovy delivering 20.7% mean weight loss that none of its new Indian rivals can currently match
Semaglutide went off patent in India on March 20, immediately drawing in generic manufacturers with prices starting as low as Rs 220 a shot. A day earlier, Novo Nordisk had secured US FDA approval for a higher-dose Wegovy delivering 20.7% mean weight loss that none of its new Indian rivals can currently match
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
